Table 1 Baseline characteristics of endometriotic patients with or without sarcopenia.
Variables | Sarcopenia | p-value | |
|---|---|---|---|
No (N = 325) | Yes (N = 48) | ||
Age (mean ± SD) | 40.0 ± 8.5 | 40.3 ± 9.7 | 0.867 |
Race* | 0.001 | ||
Mexican American | 27 (8.3%) | 3 (6.2%) | |
Other hispanic | 7 (2.2%) | 0 (0%) | |
Non-hispanic White | 232 (71.4%) | 25 (52.1%) | |
Non-hispanic Black | 50 (15.4%) | 14 (29.2%) | |
Other race | 9 (2.8%) | 6 (12.5%) | |
BMI Classification (kg/m2) | 0.483 | ||
Normal range (18.5–24.9) | 197 (60.6%) | 32 (66.7%) | |
Underweight (< 18.5) | 7 (2.2%) | 0 (0%) | |
Obese (≥ 30.0) | 121 (37.2%) | 16 (33.3%) | |
Marital status | 0.869 | ||
Married | 214 (65.8%) | 32 (66.7%) | |
Single | 111 (34.2%) | 16 (33.3%) | |
Educational level* | 0.023 | ||
College or above | 191 (58.8%) | 37 (77.1%) | |
High school or under | 134 (41.2%) | 11 (22.9%) | |
Poverty to income ratio | 0.559 | ||
Rich (≥ 1.0) | 277 (85.2%) | 43 (89.6%) | |
Poor (< 1.0) | 48 (14.8%) | 5 (10.4%) | |
Physical activity | 1.000 | ||
Yes | 261 (80.3%) | 38 (79.2%) | |
No | 64 (19.7%) | 10 (20.8%) | |
Hormonal supplement | 0.790 | ||
Yes | 125 (38.5%) | 20 (41.7%) | |
No | 199 (61.5%) | 28 (58.3%) | |
Smoking status | 0.673 | ||
Yes | 43 (13.2%) | 8 (16.7%) | |
No | 282 (86.8%) | 40 (83.3%) | |
Cardiovascular status | 0.257 | ||
Yes | 90 (27.7%) | 9 (18.8%) | |
No | 235 (72.3%) | 39 (81.2%) | |
Diabetic status | 0.997 | ||
Yes | 15 (4.6%) | 2 (4.2%) | |
No | 310 (95.4%) | 46 (95.8%) | |
Pulmonary disease | 0.899 | ||
Yes | 48 (14.8%) | 8 (16.7%) | |
No | 277 (85.2%) | 40 (83.3%) | |
Cancerous status | 0.499 | ||
Yes | 33 (10.2%) | 7 (14.6%) | |
No | 292 (89.8%) | 41 (85.4%) | |
Duration of endometriosis#* | 10.0 (5.0–17.0) | 4.0 (3.0-11.5) | < 0.001 |
Longer than five years | 247 (76%) | 19 (39.6%) | < 0.001 |
Less than five years | 78 (24%) | 29 (60.4%) | |
